Labat Africa (JSE:LAB) 12-1 Month Momentum %: -66.67% (As of Jul. 13, 2026)


What is Labat Africa 12-1 Month Momentum %?

Labat Africa JSE:LAB 12-1 Month Momentum % is -66.67% as of Jul. 13, 2026. The stock has 5 warning signs investors should review. Among 1,019 Drug Manufacturers companies, Labat Africa ranks worse than 96.07% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-13), Labat Africa's 12-1 Month Momentum % is -66.67%.

The industry rank for Labat Africa's 12-1 Month Momentum % or its related term are showing as below:

JSE:LAB's 12-1 Month Momentum % is ranked worse than
96.07% of 1019 companies
in the Drug Manufacturers industry
Industry Median: -12.44 vs JSE:LAB: -66.67

Labat Africa  (JSE:LAB) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Labat Africa 12-1 Month Momentum % Related Terms

JSE:LAB vs ZTS, UTHR, VTRS: 12-1 Month Momentum % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Labat Africa 12-1 Month Momentum % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labat Africa's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Labat Africa's 12-1 Month Momentum % falls into.


Labat Africa  (JSE:LAB) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -66.67% mean?
Labat Africa (JSE:LAB) has a 12-1 Month Momentum % of -66.67% as of Jul. 13, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Labat Africa and its competitors. According to the industry distribution chart, Labat Africa ranks #979 out of 1019 companies in the Drug Manufacturers industry, placing it in the top 96.1%.
Is Labat Africa's 12-1 Month Momentum % too high?
Labat Africa's current 12-1 Month Momentum % is -66.67%. Based on the distribution chart, Labat Africa ranks #979 out of 1019 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Labat Africa's 12-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #979 out of 1019 companies for 12-1 Month Momentum %. This places Labat Africa in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Labat Africa and its competitors. Labat Africa's current 12-1 Month Momentum % is -66.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.18, compared to a current price of R0.03 — trading 83.3% below its estimated fair value. The current 12-1 Month Momentum % is -66.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current 12-1 Month Momentum % is -66.67% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Labat Africa Business Description

Other Exchanges LAO:Germany
Address 75 Maude StreetSandown, The Leonardo 14th Floor, Sandown, Johannesburg, GT, ZAF, 1709
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.